Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation

The BCR-ABL; breakpoint cluster region-Abelson point mutation T315I is resistant to ABL tyrosine kinase inhibitors. However, axitinib, a vascular endothelial growth factor receptor inhibitor, is effective against this mutation. In this study, we investigated axitinib activity against ponatinib-resis...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Hematol Oncol
Hlavní autoři: Okabe, Seiichi, Tauchi, Tetsuzo, Tanaka, Yuko, Sakuta, Juri, Ohyashiki, Kazuma
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2015
Témata:
Letter to the Editor
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4523922/
https://ncbi.nlm.nih.gov/pubmed/26239229
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-015-0190-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky